Free Trial

This company has been marked as potentially delisted and may not be actively trading.

OTCMKTS:DCTHD

Delcath Systems (DCTHD) Stock Price, News & Analysis

Delcath Systems logo

About Delcath Systems Stock (OTCMKTS:DCTHD)

Advanced Chart

Key Stats

Today's Range
$11.74
$12.22
50-Day Range
N/A
52-Week Range
$1.22
$63,000.00
Volume
598,253 shs
Average Volume
771 shs
Market Capitalization
$482,400.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Delcath Systems, Inc. is a late-stage clinical development company with early commercial activity in Europe focused on cancers of the liver. The Company is a specialty pharmaceutical and medical device company developing its product, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS). The Company's system delivers and filters melphalan hydrochloride, which is marketed as a device under the trade name Delcath Hepatic CHEMOSAT Delivery System for Melphalan (CHEMOSAT). The Company's focus is on the execution of the clinical development program (CDP) in ocular melanoma liver metastases (mOM), intrahepatic cholangiocarncinoma (ICC), hepatocellular carcinoma (HCC or primary liver) and other cancers that are metastatic to the liver.

Receive DCTHD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Delcath Systems and its competitors with MarketBeat's FREE daily newsletter.

DCTHD Stock News Headlines

Elon Set to Shock the World by May 1st ?
Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believes will be Elon’s greatest invention ever… Yes, even bigger than Tesla or SpaceX.
See More Headlines

DCTHD Stock Analysis - Frequently Asked Questions

Delcath Systems, Inc. (OTCMKTS:DCTHD) announced its quarterly earnings data on Friday, November, 11th. The medical device company reported ($231.00) EPS for the quarter, beating analysts' consensus estimates of ($1,151.50) by $920.50. The medical device company had revenue of $0.44 million for the quarter.

Delcath Systems shares reverse split on the morning of Monday, November 6th 2017. The 1-350 reverse split was announced on Friday, November 3rd 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, November 3rd 2017. An investor that had 100 shares of stock prior to the reverse split would have 0 shares after the split.

Company Calendar

Last Earnings
11/11/2016
Today
4/25/2025

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Surgical & Medical Instruments
Sub-Industry
N/A
Current Symbol
OTCMKTS:DCTHD
Previous Symbol
NASDAQ:DCTH
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-19,220,000.00
Net Margins
-1,546.38%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$3.41 million
Price / Cash Flow
N/A
Book Value
($1,036.00) per share
Price / Book
-0.01

Miscellaneous

Free Float
N/A
Market Cap
$482,400.00
Optionable
Not Optionable
Beta
-0.03
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (OTCMKTS:DCTHD) was last updated on 4/25/2025 by MarketBeat.com Staff
From Our Partners